ETX-155

ETX-155
Clinical data
Other namesETX155
Routes of
administration		Oral
Drug classGABAA receptor positive allosteric modulator; Neurosteroid
Pharmacokinetic data
Elimination half-life24–40 hours

ETX-155 is a GABAA receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia. It is taken orally and has an elimination half-life of 24 to 40 hours. The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents. Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache. ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics. As of October 2024, development of the drug for all indications has been suspended or discontinued. It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.

See also

References

  1. 1 2 3 4 5 6 "ETX 155". AdisInsight. 8 October 2024. Retrieved 18 May 2026.
  2. 1 2 3 4 5 6 "ETX-155 Drug Profile". Ozmosi. 1 January 1900. Retrieved 18 May 2026.
  3. 1 2 3 4 5 Perucca E, White HS, Bialer M (September 2023). "New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development". CNS Drugs. 37 (9): 781–795. doi:10.1007/s40263-023-01025-4. PMC 10501930. PMID 37603261.
  4. 1 2 3 4 5 Versavel M (June 2022). "ETX-155, A novel GABAA positive allosteric modulator". Presentation given at the 2022 Epilepsy Foundation Pipeline Conference. Santa Clara, CA: Eliem Therapeutics, Inc.
  5. 1 2 3 4 "Delving into the Latest Updates on ETX-155 with Synapse". Synapse. 9 May 2026. Retrieved 18 May 2026.